α1-antitrypsin deficiency

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 545-571

  Perlmutter, David H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650383100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.025     Document Type: Chapter

References (261)

1. Sveger T. Liver disease in a1-antitrypsin deficiency detected by screening of 200, 000 infants. N Engl J Med 1976;294:1216–21.
2. Silverman EK, Miletich JP, Pierce JA, et al. Alpha-1-antitrypsin deficiency: prevalence estimation from direct population screening. Am Rev Respir Dis 1989;140:961–6.
3. Sveger T. The natural history of liver disease in alpha-1- antitrypsin deficient children. Acta Paediatr Scand 1995;77: 847–51.
4. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. N Engl J Med 1986; 314:736–9.
5. Gadek JE, Fells GA, Zimmerman RL, et al. Antielastases of the human alveolar structure: implications for the protease–antiprotease theory of emphysema. J Clin Invest 1981;68:889–98.
6. Perlmutter DH, Pierce JA. The alpha-1-antitrypsin gene and emphysema. Am J Physiol 1989;257:L147–62.
7. Janoff A. Elastases and emphysema: current assessment of the protease–antiprotease hypothesis. Am Rev Respir Dis 1985;132: 417–33.
8. Crystal RG. Alpha-1-antitrypsin deficiency, emphysema and liver disease: genetic basisandstrategies for therapy. J Clin Invest 1990;95:1343–52.
9. Carlson JA, Rogers BB, Sifers RN, et al. Accumulation of Pi Z antitrypsin causes liver damage in transgenic mice. JClin Invest 1988;83:1183–90.
10. Dyaico JM, Grant SGN, Felts K, et al. Neonatal hepatitis induced by alpha-1-antitrypsin: a transgenic mouse model. Science 1988;242:1409–12.
11. Sharp HL, Bridges RA, Krivit W. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969;73:934–9.
12. Hope PL, Hall MA, Millward-Sadler GH, et al. Alpha-1- antitrypsin deficiency presenting as a bleeding diathesis in the newborn. Arch Dis Child 1982;57:68–70.
13. Ghishan FR, Gray GF, Greene HL. a1-antitrypsin deficiency presenting with ascites and cirrhosis in the neonatal period. Gastroenterology 1983;85:435–8.
14. Zhou H, Fischer H-P. Liver carcinoma in Pi Z alpha-1- antitrypsin deficiency. Am J Surg Pathol 1998;22:742–8.
15. Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer H-P. Is heterozygous alpha-1-antitrypsin deficiency type Pi Z a risk factor for primary liver carcinoma? Cancer 2000;88:2668–76.
16. Nebbia G, Hadchouel M, Odievre M, et al. Early assessment of evolution of liver disease associated with a1-antitrypsin deficiency in childhood. J Pediatr 1983;102:661–5.
17. Ibarguen E, Gross CR, Savik SK, Sharp HL. Liver disease in a1-antitrypsin deficiency: prognostic indicators. J Pediatr 1990;117:864–70.
18. Volpert D, Molleston JP, Perlmutter DH. Alpha1-antitrypsin deficiency-associated liver disease progresses slowly in some children. J Pediatr Gastro Nutr 2000;31:258–63.
19. Starzl TE, Porter KA, Busuttil RW, et al. Liver disease in alpha-1-antitrypsin deficiency: prognostic indicators. J Pediatr 1990;117:864–70.
20. Hodges JR, Millward Sadler GH, Barbatis C, et al. Heterozygous MZa1-antitrypsin deficiency in adultswith chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med 1981;304:357–60.
21. Graziadei IW, Joseph JJ, Wiesner RH, et al. Increased risk of chronic liver failure in adults with heterozygous a1-antitrypsin deficiency. Hepatology 1998;28:1058–63.
22. Propst T, Propst A, Dietze O, et al. High prevalence of viral infections in adults with homozygous and heterozygous a1- antitrypsin deficiencyandchronic liver disease. Ann Intern Med 1992;117:641–5.
23. Reid CL, Wiener GJ, Cox DW, et al. Diffuse hepatocellular dysplasia and carcinoma associated with the Mmalton variant of a1- antitrypsin. Gastroenterology 1987;93:181–7.
24. Curiel DT, Holmes MD, Okayama H, et al. Molecular basis of the liver and lung disease associated with a1-antitrypsin deficiency allele Mmalton. J Biol Chem 1989;264:13938–45.
25. Lomas DA, Elliott PR, Sidhar SK, et al. a1-antitrypsin Mmalton [Phe52 deleted] forms loop-sheet polymers in vivo: evidence for the C-sheet mechanism of polymerization. J Biol Chem 1995;270:16864–74.
26. Mahadeva R, Chang W-SW, Dafforn TR, et al. Heteropolymerization of S, I, and Z a1-antitrypsin and liver cirrhosis. J Clin Invest 1999;103:999–1006.
27. Teckman JH, Perlmutter DH. The endoplasmic reticulum degradation pathway for mutant secretory proteins a1- antitrypsin Z and S is distinct from that for an unassembled membrane protein. J Biol Chem 1996;271:13215–20.
28. Crowley JJ, Sharp HL, Freier E, et al. Fatal liver disease associated with a1-antitrypsin deficiency PIM/PIMduarte. Gastroenterology 1987;93:242–4.
29. Clark P, Chong AYH. Rare alpha-1-antitrypsin allele PIW and a history of infant liver disease. Am J Med Genet 1992;45: 674–6.
30. Kelly CP, Tyrrell DNM, Mc Donald GSA, et al. Heterozygous FZ a1-antitrypsin deficiency associatedwith severe emphysema and hepatic disease: case report and family study. Thorax 1989; 44:758–9.
31. Eriksson S. Alpha-1-antitrypsin deficiency and liver cirrhosis in adults. Acta Med Scand 1987;221:461–7.
32. Silverman EK, Province MA, Rao DC, et al. A family study of the variability of pulmonary function in alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1990;142:1015–21.
33. Guenter CA, Welch MH, Russell TR, et al. The pattern of lung disease associated with alpha-1-antitrypsin deficiency. Arch Intern Med 1968;122:254–9.
34. Thurlbeck WM, Henderson JA, Fraser RG, et al. Chronic obstructive disease: a comparison between clinical, roentgenologic, functional and morphologic criteria in chronic bronchitis, emphysema, asthma and bronchiectasis. Medicine 1970; 49:81–98.
35. Glasgow JFT, Lynch MJ, Hercz A, et al. Alpha1 antitrypsin deficiency in association with both cirrhosis and chronic obstructive lung disease in two sibs. Am J Med 1973;54:181–94.
36. Talamo RC, Levison H, Lynch MJ, et al. Symptomatic pulmonary emphysema in childhood associated with hereditary alpha-1-antitrypsin and elastase inhibitor deficiency. J Pediatr 1971;79:20–6.
37. Houstek J, Copova M, Zapletal A, et al. Alpha1-antitrypsin deficiency in a childwith chronic lung disease. Chest 1973;64:773–6.
38. Dunand P, Cropp GA, Middleton E Jr. Severe obstructive lung disease in a 14-year-old girlwith alpha-1 antitrypsin deficiency. J Allergy Clin Immunol 1975;57:615–22.
39. Wagener JS, Sobonya RE, Taussig LM, et al. Unusual abnormalities in adolescent siblingswith a1-antitrypsin deficiency. Chest 1983;83:464–8.
40. Hird MF, Greenough A, Mieli-Vergani G, et al. Hyperinflation in children with liver disease due to a1-antitrypsin deficiency. Pediatr Pulmonol 1991;11:212–16.
41. Wiebicke W, Niggermann B, Fischer A. Pulmonary function in children with homozygous alpha-1-protease inhibitory deficiency. Eur J Pediatr 1996;155:603–7.
42. Larsson C. Natural history and life expectancy in severe alpha-1- antitryspin deficiency, Pi Z. Acta Med Scand 1978;204:345–51.
43. Janus ED, Phillips NT, Carrell RW. Smoking, lung function and alpha-1-antitrypsin deficiency. Lancet 1985;I:152–4.
44. Schonfeld JV, Brewer N, Zotz, R, et al. Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (PIZZ). Digestion 1996;57:165–9.
45. Huber R, Carrell RW. Implications of the three-dimensional structure of alpha-1-antitrypsin for structure and function of serpins. Biochemistry 1990;28:8951–66.
46. Vaughan L, Lorier MA, Carrell RW. Alpha-1-antitrypsin microheterogeneity: isolation and physiological significance of isoforms. Biochim Biophys Acta 1982;701:339–45.
47. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions and a revised nomenclature. J Biol Chem 2000; 276:33293–6.
48. Elliott PR, Lomas DA, Carrell RW, et al. Inhibitory conformation of the reactive loop of a1-antitrypsin. Nat Struct Biol 1996;3:676–81.
49. Elliott PR, Abrahams J-P, Lomas DA. Wild-type a1-antitrypsin is in the cannonical inhibitory conformation. J Mol Biol 1998; 275:419–25.
50. Owen MC, Brennan SO, Lewis JH, et al. Mutation of antitrypsin to antithrombin: alpha-1-antitrypsin Pittsburgh (358 Met-Arg), a fatal bleeding disorder. N Engl J Med 1983;309: 694–8.
51. Banda MJ, Rice AG, Griffin GL, et al. Alpha-1-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. J Biol Chem 1988;263:4481–4.
52. Banda MJ, Rice AG, Griffin GL, et al. The inhibitory complex of humanalpha-1-proteinase inhibitor andhumanleukocyte elastase is a neutrophil chemoattractant. J Exp Med 1988;167:1608–15.
53. Perlmutter DH, Glover GI, Rivetna M, et al. Identification of a serpin-enzyme complex (SEC) receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci U S A 1990;87:3753–7.
54. Perlmutter DH, Joslin G, Nelson P, et al. Endocytosis and degradation of alpha-1-antitrypsin-proteinase complexes is mediated by the SEC receptor. J Biol Chem 1990;265:16713–16.
55. Long GL, Chandra T, Woo SLC, et al. Complete nucleotide sequence of the c DNA for human alpha-1-antitrypsin and the gene for the S variant. Biochemistry 1984;23:4828–37.
56. Lai EC, Kao F-F, Law ML, et al. Assignment of the alpha-1- antitrypsin gene and sequence-related gene to human chromosome 14 by molecular hybridization. Am J Hum Genet 1983; 35:385–92.
57. Pearson SJ, Tetri P, George DL, et al. Activation of human alpha-1-antitrypsin gene in rat hepatoma x human fetal liver cell hybrids depends on presence of human chromosome 14. Somat Cell Mol Genet 1983;9:567–92.
58. Rabin M, Watson M, Kidd V, et al. Activation of human alpha- 1-antichymotrypsin and alpha-1-antitrypsin genes on human chromosome 14. Somat Cell Mol Genet 1986;12:209–14.
59. Perlino E, Cortese R, Ciliberto G. The human alpha-1- antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. EMBO J 1987;6:2767–71.
60. Hofker MH, Nelen M, Klasen EC, et al. Cloning and characterization of an alpha-1-antitrypsin-like gene 12 kb downstream of the genuine alpha-1-antitrypsin gene. Biochem Biophys Res Comm 1988;155:634–42.
61. Kelsey GD, Parker M, Povey S. The human alpha-1-antitrypsinrelated sequence gene: isolation and investigation of its sequence. Ann Hum Genet 1988:52:151–60.
62. Sefton L, Kelsey G, Kearney P, et al. A physical map of human PI and AACT genes. Genomics 1990;7:382–8.
63. Seralini G-E, Berube D, Gagne R, et al. The human corticosteroid binding globulin gene is located on chromosome14q31- q32. 1 near two other serine protease inhibitor genes. Hum Genet 1990;80:75–8.
64. Hafeez W, Ciliberto G, Perlmutter DH. Constitutive and modulated expression of the human alpha-1-antitrypsin gene: different transcriptional initiation sites used in three different cell types. J Clin Invest 1992;89:1214–22.
65. Pierce JA, Erdio BG. Improved identification of antitrypsin phenotypes through isoelectric focusing with dithioerythritol. J Lab Clin Med 1979;94:826–31.
66. Barker A, Brantly M, Campbell E, et al. a1-antitrypsin deficiency: memorandumfroma WHOmeeting. Bull World Health Organ 1997;75:397–415.
67. Nukiwa T, Brantly ML, Ogushi F, et al. Characterization of the M1 (ala 213) type of alpha-1-antitrypsin haplotype. Biochemistry 1987;26:5259–67.
68. Dykes D, Miller S, Polesky H. Distribution of alpha-1- antitrypsin variants in a U. S. white population. Hum Hered 1984;34:308–10.
69. Kueppers F, Christopherson MJ. Alpha-1-antitrypsin: further genetic heterogeneity revealed by isoelectric focusing. Am J Hum Genet 1978;85:381–2.
70. Graham A, Hayes K, Weidinger S, et al. Characterization of alpha-1-antitrypsin M3 gene, a normal variant. Hum Genet 1990;85:381–2.
71. Jeppsson J-O, Laurell C-B. The amino acid substitutions of human alpha-1-antitrypsin M3, X and Z. FEBS Lett 1988;231: 327–30.
72. Brennan SO, Carrell RW. Alpha-1-antitrypsin Christchurch, 363Glu-Lys: mutation at the P_5 position does not affect inhibitory activity. Biochim Biophys Acta 1986;573:13–19.
73. Holmes MD, Brantly ML, Crystal RG. Molecular analysis of the heterogeneity among the P-family of alpha-1-antitrypsin alleles. Am Rev Respir Dis 1990;142:1185–92.
74. Talamo RC, Langley CE, Reed CE, et al. Alpha-1-antitrypsin deficiency: a variant with no detectable alpha-1-antitrypsin. Science 1973;181:70–1.
75. Takahashi H, Crystal RG. Alpha-1-antitrypsin null isola di procida: alpha-1-antitrypsin deficiency allele caused by deletion of all alpha-1-antitrypsin coding exons. Am J Hum Genet 1990;47:403–13.
76. Poller W, Faber J-P, Neidinger S, et al. DNA polymorphisms associatedwith a new alpha-1-antitrypsin PIQO variant (PIQO reidenberg). Hum Genet 1991;86:522–4.
77. Garver RI, Mornex J-P, Nukiwa T, et al. Alpha-1-antitrypsin deficiency and emphysema caused by homozygous inheritance of on-expressing alpha-1-antitrypsin genes. N Engl J Med 1986;314:762–6.
78. Satoh K, Nukiwa T, Brantly M, et al. Emphysema associated with complete absence of alpha-1-antitrypsin in serum and the homozygous inheritance of stop codon in an alpha-1- antitrypsin coding exon. Am J Hum Genet 1988;42:77–83.
79. Holmes M, Curiel D, Brantly M, et al. Characterization of the intracellular mechanism causing the alpha-1-antitrypsin Nullgranite falls deficiency state. Am Rev Respir Dis 1989;140: 1662–7.
80. Nukiwa T, Takahashi H, Brantly M, et al. Alpha-1-antitrypsin Nullgranite Falls: a nonexpressing alpha-1-antitrypsin gene associated with a frameshift stop mutation in a coding exon. J Biol Chem 1987;262:11999–2004.
81. Curiel D, Brantly M, Curiel E, et al. Alpha-1-antitrypsin deficiency caused by the alpha-1-antitryspin null mattawa gene: an insertion mutation rendering the alpha-1-antitrypsin gene incapable of producing alpha-1-antitrypsin. J Clin Invest 1989;83:1144–52.
82. Muensch H, Gaidulis L, Kueppers F, et al. Complete absence of serum alpha-1-antitrypsin in conjunction with an apparently normal gene structure. Am J Hum Genet 1986;38:898–907.
83. Sifers RN, Brashears-Macatee S, Kidd VJ, et al. A frameshift mutation results in a truncated alpha-1-antitrypsin that is retained within the rough endoplasmic reticulum. J Biol Chem 1988;263:7330–5.
84. Brantly M, Lee JH, Hildeshiem J, et al. a1-antitrypsin gene mutation hot spot associated with the formation of a retained and degraded null variant. Am J Respir Cell Mol Biol 1997; 16:224–31.
85. Carrell RW. Alpha-1-antitrypsin molecular pathology, leukocytes and tissue damage. J Clin Invest 1986;77:1427–31.
86. Curiel D, Chytil A, Courtney M, et al. Serum alpha-1- antitrypsin deficiency associated with the common S-type (Glu364-Val) mutation results in intracellular degradation of alpha-1-antitrypsin prior to secretion. J Biol Chem 1989;264: 10477–86.
87. Hofker MH, Nukiwa T, Van Paassen HMB, et al. A Pro-Leu substitution in codon 369 in the alpha-1-antitrypsin deficiency variant Pi Mheerlen. Am J Hum Genet 1987;41:A220 [abstract].
88. Takahashi H, Nukiwa T, Satoh K, et al. Characterization of the gene and protein of the alpha-1-antitrypsin “deficiency” allele M procida. J Biol Chem 1988;263:15528–34.
89. Sproule BJ, Cox SW, Hsu K, et al. Pulmonary function associatedwith the Mmalton deficient variant of alpha-1-antitrypsin. Am Rev Respir Dis 1983;127:237–40.
90. Curiel DT, Vogelmeier C, Hubbard RC, et al. Molecular basis of alpha-1-antitrypsin deficiency and emphysema associated with alpha-1-antitrypsin M mineral springs allele. Mol Cell Biol 1990;10:47–56.
91. Holmes MD, Brantley ML, Fells GA, et al. Alpha-1- antitrypsin WBethesda: molecular basis of an unusual alpha-1- antitrypsin deficiency variant. Biochem Biophys Res Comm 1990;170:1013–22.
92. Seyama K, Nukiwa T, Takabe K, et al. Siiyama serine 53 [TCC] to phenylalanine 53 (TTC): a new alpha-1-antitrypsin deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991;266:12627–32.
93. Okayama H, Brantly M, Holmes M, et al. Characterization of the molecular basis of the alpha-1-antitrypsin F allele. Am J Hum Genet 1991;47:1154–8.
94. Graham A, Kalsheker NA, Bamforth FJ, et al. Molecular characterization of two alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) Null newport (Gly165-Ser) and (Pi) Z Wrexham (Ser-19-Leu). Hum Genet 1990;85:537–40.
95. Senior RM, Tegner H, Kuhn C, et al. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 1977;116:469–75.
96. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655–709.
97. Carp H, Janoff A. Possible mechanisms of emphysema in smokers: in vitro suppression of serum elastase inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Respir Dis 1978;118:617–21.
98. Ossanna PJ, Test S, Matheson NR, et al. Oxidative regulationand neutrophil elastase-alpha-1-proteinase inhibitor interactions. J Clin Invest 1986;72:1939–51.
99. Hubbard RC, Ogushi F, Fells GA, et al. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of a1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest 1987;80: 1289–95.
100. Mast AE, Enghild J, Nagase H, et al. Kinetics and physiologic relevance of the inactivation of a1-proteinase inhibitor, a1-antichymotrypsin, and antithrombin III by matrix metalloproteinases- 1 (tissue collagenase), -1 (72-k Da gelatinase/ type IV collagenase), and -3 (stromelysin). J Biol Chem 1991; 266:15810–16.
101. Bathurst IC, Travis J, George PM, et al. Structuralandfunctional characterization of the abnormal Za1-antitrypsin isolated from human liver. FEBS Lett 1984;177:179–83.
102. Ogushi F, Fells GA, Hubbard RC, et al. Z-type a1-antitrypsin is less competent than M1-type a1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;89:1366–74.
103. Libert C, Van Molle W, Brouckaert P, et al. a1-antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996; 157:5126–9.
104. Van Molle W, Libert C, Fiers W, et al. a1-acid glycoprotein and a1-antitrypsin inhibit TNF-induced, but not anti-Fasinduced apoptosis of hepatocytes in mice. J Immunol 1997;159: 3555–64.
105. Camussi G, Tetta C, Bussolino F, et al. Synthesis and release of platelet-activating factor is inhibited by plasma a1-proteinase inhibitor or a1-antichymotrypsin and is stimulated by proteinases. J Exp Med 1988;168:1293–306.
106. Joslin G, Griffin GLI, August AM, et al. The serpin-enzyme complex [SEC] receptor mediate the neutrophil chemotactic effect of a1-antitrypsin-elastse complexes and amyloid-ß peptide. J Clin Invest 1992;90:1150–4.
107. Wilson-Cox D. Alpha-1-antitrypsin deficiency. In: Scriber CB, Beaudet AL, Aly QA, eds. The metabolic basis of inherited disease. New York: Mc Graw-Hill, 1989:2409–37.
108. Breit SN, Wakefield D, Robinson JP, et al. The role of alpha-1- antitrypsin deficiency in the pathogenesis ofimmune disorders. Clin Immun Immunopathol 1985;35:363–80.
109. Hood JM, Koep LJ, Peters RL, et al. Liver transplantation for advanced liver disease with a1-antitrypsin deficiency. N Engl J Med 1980;302:272–6.
110. Lodish HF, Kong N. Glucose removal from N-linked oligosaccharides is required for efficient maturation of certain secretory glycoproteins from the rough endoplasmic reticulum to the Golgi complex. J Cell Biol 1987;104:221–30.
111. Liu M-C, Yu S, Sy J, et al. Tyrosine sulfation of proteins from human hepatoma cell line Hep G2. Proc Natl Acad Sci U S A 1985;82:7160–4.
112. De Simone V, Cortese R. Transcription factors and liver-specific genes. J Biol Biophys Acta 1992;1132:119–26.
113. Tripodi M, Abbott C, Vivian M, et al. Disruption of the LFA1 and LF-B1, binding sites in the human alpha-1-antitrypsin gene, has a differential effect during development in transgenic mice. EMBO J 1991;10:3177–82.
114. Hu C, Perlmutter DH. Regulation of a1-antitrypsin gene expression in human intestinal epithelial cell line Caco2 by HNF1a and HNF4. Am J Physiol 1999;276:G1181–94.
115. Dickson I, Alper CA. Changes in serum proteinase inhibitor levels following bone surgery. Clin Chim Acta 1974;54:381–5.
116. Perlmutter DH, May LT, Sehgal PB. Interferon ß2interleukin- 6 modulates synthesis of a1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest 1989;264:9485–90.
117. Laurell C-B, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy and estrogens. J Clin Endocrinol Metab 1979;49:719–25.
118. Perlmutter DH, Cole FS, Kilbridge P, et al. Expression of the a1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci U S A 1985;82:795–9.
119. Barbey-Morel C, Pierce JA, Campbell EJ, et al. Lipopolysaccharide modulates the expression of a1-proteinase inhibitor and other serine proteinase inhibitors in human monocytes and macrophages. J Exp Med 1987;166:1041–54.
120. Perlmutter DH, Travis J, Punsal PI. Elastase regulates the synthesis of its inhibitors, a1-proteinase inhibitor, and exaggerates the defect in homozygous PIZZ a1-proteinase inhibitor deficiency. J Clin Invest 1988;81:1774–8.
121. Joslin G, Fallon RJ, Bullock J, et al. The SEC receptor recognizes a pentapeptide neo-domain of a1-antitrypsin-protease complexes. J Biol Chem 1991;266:11281–8.
122. Joslin G, Wittwer A, Adams S, et al. Cross-competition for binding of a1-antitrypsin (a-1-AT)-elastase complexes to the serpin-enzyme complex receptor by other serpin-enzyme complexes and by proteolytically modified a-1-AT. J Biol Chem 1993;268:1886–93.
123. Joslin G, Krause JE, Hershey ED, et al. Amyloid-ß peptide, substance P and bombesin bind to the serpin-enzyme complex receptor. J Biol Chem 1991;266:21897–902.
124. Boland K, Behrens M, Choi D, et al. The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-ß peptide but not aggregated, cytotoxic amyloid-ß peptide. J Biol Chem 1996;271:18032–44.
125. Mast AE, Enghild JJ, Pizzo SV, et al. Analysis of plasma elimination kinetics and conformation stabilities of native, proteinasecomplexed and reactive site cleaved serpins: comparison of a1- proteinase inhibitor, a1-antichymotrypsin, antithrombin III, a2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991;30:1723–30.
126. Poller W, Willnow TE, Hilpert J, et al. Differential recognition of a1-antitrypsin-elastase and a1-antichymotrypsin-cathespin G complexes by the low density lipoprotein receptor-related protein. J Biol Chem 1995;270:2841–5.
127. Kounnas MZ, Church FC, Argraves WS, et al. Cellular internalization and degradation of antithrombin-IIIthrombin, heparin cofactor II-thrombin, and a1-antitrypsintrypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996;271:6523–9.
128. Kelsey GD, Povey S, Bygrave AE, et al. Species-and tissuespecific expression of human alpha-1-antitrypsin in transgenic mice. Genes Dev 1987;1:161–70.
129. Koopman P, Povey S, Lovel-Badge RH. Widespread expression of human alpha-1-antitrypsin in transgenic mice revealed by in situ hybridization. Genes Dev 1989;3:16–25.
130. Carlson JA, Rogers BB, Sifers RN, et al. Multiple tissues express alpha-1-antitrypsin in transgenic mice and man. J Clin Invest 1988;82:26–36.
131. Molmenti EP, Perlmutter DH, Rubin DC. Cell-specific expression of a1-antitrypsin in human intestinal epithelium. J Clin Invest 1993;92:2022–34.
132. Venembre P, Boutten A, Seta N, et al. Secretion of a1- antitryupsin by alveolar epithelial cells. FEBS Lett 1994;346: 171–4.
133. Cichy J, Potempa J, Travis J. Biosynthesis of a1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem 1997;272:8250–5.
134. Makino S, Reed CE. Distribution and elimination of exogenous alpha-1-antitrypsin. J Lab Clin Med 1977;52:457–61.
135. Laurell C-B, Nosslin B, Jeppsson J-O. Catabolic rate of a1- antitrypsin of P1 type Mand Z in man. Clin Sci Mol Med 1977; 52:457–61.
136. Thomas DW, Sinatra FR, Merritt RJ. Random fecal alpha-1- antitrypsin concentration in children with gastrointestinal disease. Gastroenterology 1981;80:776–82.
137. Grill B, Tinghitella T, Hillemeier C, et al. Increased intestinal clearance of alpha-1-antitrypsin in patient with alpha-1- antitrypsin deficiency. J Pediatr Gastroenterol Nutr 1983;2: 95–8.
138. Kidd VJ, Walker RB, Itakura K, et al. a1-antitryupsin deficiency detection by direct analysis of themutation of the gene. Nature (London) 1983;304:230–4.
139. Jeppsson J-O. Amino acid substitution Glu-Lys in a1- antitrypsin Pi Z. FEBS Lett 1976;65:195–7.
140. Owen MC, Carrell RW. a1-antitrypsin: sequence of the Zvariant tryptic peptide. FEBS Lett 1976;79:247–9.
141. Perlmutter DH, Kay RM, Cole FS, et al. The cellular defect in a1-proteinase inhibitor deficiency is expressed inhumanmonocytes and xenopus oocytes injected with human liver m RNA. Proc Natl Acad Sci U S A 1985;82:6918–21.
142. Foreman RC, Judah JD, Colman A. Xenopus oocytes can synthesizebutdonot secrete the Zvariant ofhumana1-antitrypsin. FEBS Lett 1984;169:84–8.
143. McCracken AA, Kruse KB, Brown JL. Molecular basis for defective secretion of variants having altered potential for salt bridge formation between amino acids 240 and 242. Mol Cell Biol 1989;9:1408–14.
144. Sifers RN, Hardick CP, Woo SLC. Disruption of the 240–342 salt bridge is not responsible for the defect of the PIZ a1-antitrypsin variant. J Biol Chem 1989;264:2997–3001.
145. Wu Y, Foreman RC. The effect of amino acid substitutions at position 342 on the secretion of human a1-antitrypsin from xenopus oocytes. FEBS Lett 1990;268:21–3.
146. Lomas DA, Evans DL, Finch JJ, et al. The mechanism of Z a1-antitrypsin accumulation in the liver. Nature 1992;357: 605–7.
147. Lomas DA, Finch JT, Seyama K, et al. a1-antitrypsin Siiyama (SER53?Phe): further evidence for intracellular loop-sheet polymerization. J Biol Chem 1993;268:15333–5.
148. Elliott PR, Stein PE, Bilton D, et al. Structural explanation for the deficiency of S a1-antitrypsin. Nature Struct Biol 1996;3: 910–11.
149. Sidhar SK, Lomas DA, Carrell RW, et al. Mutations which impede loop-sheet polymerization enhance the secretion of human a1-antitrypsin deficiency variants. J Biol Chem 1995; 270:8393–6.
150. Kang HA, Lee KN, Yu M-H. Folding and stability of the Z and Siiyama genetic variants of human a1-antitrypsin. J Biol Chem 1997;272:510–16.
151. Lin L, Schmidt B, Teckman J, Perlmutter DH. Anaturally occurring non-polymerogenic mutant of a1-antitrypsin characterized by prolonged retention in the endoplasmic reticulum. J Biol Chem 2001;276:33893–8.
152. Schmidt BZ, Perlmutter DH. GRP78, GRP94 and GRP170 interact with a1 AT mutants that are retained in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol 2005;289:G444–55.
153. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization ofmutant neuroserpin. Nature 1999; 401:376–9.
154. Kamimoto T, Shoji S, Mizushima N, et al. Intracellular inclusions containingmutant a1 ATZ are propagated in the absence of autophagy. J Biol Chem 2006;281:4467–76.
155. Kruse KB, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble a1 Pi Z and another for aggregates of a1 Pi Z. Mol Biol Cell 2006;17:203–12. Epub 2005 Nov 2.
156. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH. Accumulation of mutant a1-antitrypsin Z in the ER activates caspases-4 and -12, NF?B and BAP31 but not the unfolded protein response. J Biol Chem 2005;280:39002–15. Epub 2005 Sep 23.
157. Wu Y, Whitman I, Molmenti E, et al. Alag in intracellular degradation ofmutant a1-antitrypsin correlateswith the liver disease phenotype inhomozygous Pi ZZa1-antitrypsin deficiency. Proc Natl Acad Sci U S A 1994;91:9014–18.
158. Werner ED, Brodsky JL, McCracken AA. Proteasomedependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc Natl Acad Sci U S A 1996;93:13797–801.
159. Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of mutant secretory protein, a1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996;271:22791–5.
160. Teckman JH, Gilmore R, Perlmutter DH. Role of ubiquitin in proteasomal degradation of mutant a1-antitrypsin Z in the endoplasmic reticulum. Am J Physiol 2000;278:G39–48.
161. Teckman JH, Burrows J, Hidvegi T, et al. The proteasome participants in degradation of mutant a1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes. JBiol Chem 2001;276:44865–72.
162. Cabral CM, Liu Y, Moremen KW, Sifers RN. Organizational diversity among distinct glycoprotein endoplasmic reticulumassociated degradation programs. Mol Biol Cell 2002;13: 2639–50.
163. Mayer T, Braun T, Jentsch S. Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein. EMBO J 1998;17:3251–7.
164. Cabral CM, Choudhury P, Liu Y, Sifers RN. Processing by endoplasmic reticulum mannosidases partitions a secretionimpaired glycoprotein into distinct disposal pathways. J Biol Chem 2000;275:25015–22.
165. Teckman JH, Perlmutter DH. Retention of mutant a1- antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol 2000;279:G961–74.
166. Teckman JH, An JK, Blomenkamp K, et al. Mitochondrial autophagy and injury in the liver in a1-antitrypsin deficiency. Am J Physiol 2004;286:G851–62.
167. Perkins G, Renken C, Martone ME, et al. Electron tomography of neuronal mitochondria: three-dimensional structure and organization of cristae and membrane contacts. J Struct Biol 1997;119:260–72.
168. Achleitner G, Gaigg B, Krasser A, et al. Association between the endoplasmic reticulum and mitochondria of yeast facilitates intraorganelle transport of phospholipids through membrane contact. Eur J Biochem 1999;264:545–53.
169. Mizushima N, Yamamoto A, Matsui M, et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004;15:1101–11.
170. Zhang K, Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 2004;279: 25935–8.
171. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002;110:1383–8.
172. Pahl HL, Sester M, Burgert HG, Baeuerle PA. Activation of transcription factor NF?B by the adenovirus E3/19K protein requires its ER retention. J Cell Biol 1996;132:511–22.
173. Hu C, Perlmutter DH. Cell-specific involvement of HNF-1ß in a1-antitrypsin gene expression in human respiratory epithelial cells. Am J Physiol 2002;282:L757–65.
174. Pikarsky E, Porat RM, Stein I, et al. NF?B functions as a tumor promoter in inflammation-associated cancer. Nature 2004;431:461–6.
175. Greten FR, Eckman L, Greten TF, et al. IKKß links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285–96.
176. Maeda S, Kamata H, Luo J-L, et al. IKKß couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005;121:977–90.
177. Schamel WW, Kuppig S, Becker B, et al. A high-molecularweight complex of membrane proteins BAP29/BAP31 is involved in the retention of membrane-bound Ig D in the endoplasmic reticulum. Proc Natl Acad Sci U S A 2003;100:9861–6.
178. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol 2003;160:1115–27.
179. Povey S. Genetics of a1-antitrypsin deficiency in relation to neonatal liver disease. Mol Biol Med 1990;7:161–2.
180. Dougherty DG, Donaldson PT, Whitehouse DB, et al. HLAphenotype and gene polymorphism in juvenile liver disease associated with a1-antitrypsin deficiency. Hepatology 1990;12:218–23.
181. Lobo-Yeo A, Senaldi G, Portmann R, et al. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990;12:224–32.
182. Sargent CA, Dunham I, Trowsdale J, et al. Human major histocompatibility complex contains genes for the major heat shock protein HSP 70. Proc Natl Acad Sci U S A 1989;1968–77.
183. Albertella MR, Jones H, Thomson W, et al. Localisation of eight additional genes in the human major histocompatibility complex, including the gene encoding the casein kinase II beta subunit, and DNA sequence analysis of the class III region. DNA Sequence 1996;7:9–12.
184. Geller SA, Nichols WS, Dycacio MJ, et al. Histopathology of a1-antitrypsin liver disease in a transgenic mouse model. Hepatology 1990;12:40–7.
185. Geller SA, Nichols WS, Kim SS, et al. Hepatocarcinogenesis is the sequel to hepatitis in Z#2 a1-antitrypsin transgenic mice: histopathological and DNA ploidy studies. Hepatology 1994;19:389–97.
186. Gaczynska M, Rock KL, Goldber AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993;365:264–7.
187. Bathurst IC, Errington DM, Foreman RC, et al. Human Zalpha- 1-antitrypsin accumulates intracellularly and stimulates lysosomal activity when synthesized in the xenopus oocyte. FEBS Lett 1985;183:304–8.
188. Raposo G, van Santen HM, Liejendekker R, et al. Misfolded major histocompatibility complex class I molecules accumulate in an expanded ER-Golgi intermediate compartment. JCell Biol 1995;131:1403–19.
189. Dunn WA. Studies on the mechanism of autophagy: formation of autophagic vacuole. J Cell Biol 1991;110:1923–33.
190. Mizushima N, Noda T, Yoshimori T, et al. Aprotein conjugation system essential for autophagy. Nature 1998;195:395–8.
191. Klionsky DJ. Autophagy. Curr Biol 2005;15:R282–3.
192. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883–98.
193. Anton LC, Schubert U, Bacik I, et al. Intracellular localization of proteasomal degradation of a viral antigen. J Cell Biol 1999;146:113–24.
194. Teckman JH, An J-K, Loethen S, Perlmutter DH. Effect of fasting on liver in a mouse model of a1-antitrypsin deficiency: constitutive activation of the autophagic response. Am J Physiol 2002;283:61117–24.
195. Tanka Y, Guhde G, Suter A, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000;406:902–6.
196. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy andmyopathy (Danon disease). Nature 2000;406:906–10.
197. Elmore SP, Qian T, Grissom DF, Lemasters JJ. The mitochondrial permeability transition initiates autophagy in rat hepatocytes. FASEB J 2001;15:2286–7.
198. Perkins G, Renken C, Martone ME, et al. Electron tomography of neuronal mitochondria: three-dimensional structure and organization of cristae and membrane contacts. J Struct Biol 1997;119:260–72.
199. Achleitner G, Gaigg B, Krasser A, et al. Association between the endoplasmic reticulum and mitochondria of yeast facilitates interorganelle transport of phospholipids through membrane contact. Eur J Biochem 1999;264:545–53.
200. Wang H-J, Guay G, Pogan L, et al. Calcium regulates the association between mitochondria and a smooth subdomain of the endoplasmic reticulum. J Cell Biol 2000;150:1489–97.
201. Arnaudeau S, Kelley WL, Walsh JV, Demaurex N. Mitochondria recycle Ca2+ to the endoplasmic reticulum and prevent the depletion of neighboring endoplasmic reticulum regions. J Biol Chem 2001;276:29430–9.
202. Hacki J, Egger L, Monney L, et al. Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 2000;19:2286–95.
203. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK; a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727–30.
204. Rudnick DA, Liao Y, An JK, et al. Analyses of hepatocellular proliferation in a mouse model of a1-antitrypsin deficiency. Hepatology 2004;39:1048–55.
205. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000;2:645–52.
206. Perlmutter DH, Schlesinger MJ, Pierce JA, et al. Synthesis of stress proteins is increased in individuals with homozygous Pi ZZ a1-antitrypsin deficiency and liver disease. J Clin Invest 1989;84:1555–61.
207. Vogel A, van Den Berg IE, Al-Dhalimy M, et al. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology 2004;39:433–43.
208. Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P. Selfinduced correction of the genetic defect in tyrosinemia type I. J Clin Invest 1994;94:1657–61.
209. Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996;12:266–73.
210. Demers SI, Russo P, Lettre F, Tanguay RM. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia. Hum Pathol 2003;34:1313–20.
211. Mc Lachlan A, Milich DR, Raney AK, et al. Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol 1987;61:683–92.
212. Wang HC, Wu HC, Chen CF, et al. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-Smutants that may induce endoplasmic reticulum stress. Am J Pathol 2003;163:2441–9.
213. Dubuisson J. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 2000;242:135–48.
214. Yang SQ, Lin HZ, Hwang J, et al. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001;61:5016–23.
215. Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301–11.
216. Johnson K, Alton HM, Chapman S. Evaluation of mebrofenin hepatoscintigraphy in neonatal-onset jaundice. Pediatr Radiol 1998;28:937–41.
217. Nord KS, Saad S, Joshi VV, et al. Concurrence of a1-antitrypsin deficiency and biliary atresia. J Pediatr 1987;111:416–18.
218. Ghishan FK, Greene HL. Inborn errors of metabolism that lead to permanent liver injury. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. Philadelphia: WB Saunders, 1982:1351.
219. Mowat AP. Hepatitis and cholestasis in infancy: intrahepatic disorders. In: Mowat AP, ed. Liver disorders in childhood. London: Butterworth, 1982:50.
220. Qizibash A, Yong-Pong O. Alpha-1-antitrypsin liver disease: differential diagnosis of PAS-positive diastase-resistant globules in liver cells. Am J Clin Pathol 1983;79:697–702.
221. Yunis EJ, Agostini RM, Glew RH. Fine structural observations of the liver in a1-antitryspin deficiency. Am J Clin Pathol 1976;82:265–86.
222. Tobin MJ, Cook PJL, Hutchison DCS. Alpha-1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. Br J Dis Chest 1983;77:14–27.
223. Udall JN, Dixon M, Newman AP, et al. Liver disease in a1- antitrypsin deficiency: a retrospective analysis of the influence of early breast- vs bottle-feeding. JAMA 1985;253:2679–82.
224. Udall JN, Bloch KJ, Walker WA. Transport of proteases across neonatal intestine and development of liver disease in infants with a1-antitrypsin deficiency. Lancet 1982;ii:1441–3.
225. Kayler LK, Merion RM, Lee S, et al. Long-term survival after liver transplantation in childrenwith metabolic disorders. Pediatr Transplant 2002;6:295–300.
226. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angiodema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 1976;195:1444–8.
227. Gadek JE, Fulmer JD, Gelfand JA, et al. Danazol-induced augmentation of serum alpha-1-antitrypsin levels in individuals with marked deficiency of this anti-protease. J Clin Invest 1980;66:82–7.
228. Wewers MD, Gadek JE, Loegh BA, et al. Evaluation of danazol therapy for patients with Pi ZZ alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1986;134:476–80.
229. Sato S, Ward CL, Krouse ME, et al. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996;271:635–8.
230. Tatzelt J, Prusiner SB, Welch WJ. Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J 1996;15:6363–73.
231. Tamarappoo B, Verkman AS. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 1998;101:2257–67.
232. Brown CR, Hong-Brown LQ, Welch WJ. Correcting temperature- sensitive protein folding defects. J Clin Invest 1997; 99:1432–44.
233. Fan J-Q, Ishii S, Asano N, et al. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112–15.
234. Burrows JAJ, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant a1-antitrypsin (a1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in a1-AT deficiency. Proc Natl Acad Sci U S A 2000;97:1796–801.
235. Jacob GS. Glycosylation inhibitors in biology and medicine. Curr Opin Struct Biol 1995;5:605–11.
236. Zitzmann N, Mehta AS, Carrouee S, et al. Imino sugars inhibit the formationand secretion ofbovine viral diarrhea virus, apestivirus model of hepatitis C virus: implications for the development of broad-spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A 1999;96:11878–82.
237. Marcus NY, Perlmutter DH. Glucosidase and mannosidase inhibitors mediate increased secretion of mutant a1- antitrypsin Z. J Biol Chem 2000;275:1987–92.
238. Abboud RT, Ford GT, Chapman KR. Emphysema in alpha1antitrypsin deficiency: Does replacement therapy affect outcome? Treat Respir Med 2005;4:1–8.
239. Cassivi SD, Meyers BF, Battafarano RJ, et al. Thirteen year experience in lung transplantation foremphysema. Ann Thorac Surg 2002;74:1663–9.
240. Anderson WF. The current status of clinical gene therapy. Hum Gene Ther 2002;13:1261–2.
241. Long MB, Jones JP, Sullenger BA, Byun J. Ribozyme-mediated revision of RNA and DNA. J Clin Invest 2003;112:312–18.
242. Garcia-Blanco MA. Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J Clin Invest 2003; 112:474–80.
243. Kren BT, Bandyopadhyay P, Steer CJ. Invivosite-directedmutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med 1998;4:285–90.
244. Metz R, Dicola M, Kurihara T, et al. Mode of action of RNA/DNA oligonucleotides. Chest 2002;121:915–25.
245. Kmiec EB. Targeted gene repair –in the arena. JClin Invest 2003; 112:632–6.
246. Seidman MM, Glazier PM. The potential for gene repair via triple helix formation. J Clin Invest 2003;114:487–94.
247. Gruenert DC, Bruscia E, Novelli G, et al. Sequence-specific modification of genomic DNA by small DNA fragments. J Clin Invest 2003;112:637–41.
248. Davidson BL. Hepatic diseases –hitting the target with inhibitory RNAs. N Engl J Med 2003;349:2357–9.
249. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirusbased system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Gen 2003;33:401–6.
250. Rhim JA, Sandgen EP, Degen JL, et al. Replacement of disease mouse liver by hepatic cell transplantation. Science 1994; 263:1149–52.
251. Day PM, Yewdell JW, Porgador A, et al. Direct delivery of exogenous MHCclass I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc Natl Acad Sci US A 1997; 94:8064–9.
252. Johannes L, Goud B. Surfing on a retrograde wave: how does Shiga toxin reach the endoplasmic reticulum? Trends Cell Biol 1998;8:158–62.
253. Lord, JM, Roberts LM. Toxin entry: retrograde transport through the secretory pathway. J Cell Biol 1998;140:733–6.
254. Kidd VJ, Golbus MS, Wallace RB, et al. Prenatal diagnosis of alpha-1-antitrypsin deficiency by direct analysis of the mutation site in the gene. N Engl J Med 1984;310:639–42.
255. Cox DW, Mansfield T. Prenatal diagnosis of alpha-1-antitrypsin deficiency and estimates of fetal risk for disease. J Med Genet 1987;24:52–9.
256. Nukiwa T, Brantly M, Garver R, et al. Evaluation of “at risk” alpha-1-antitrypsin genotype SZ with synthetic oligonucleotide gene probes. J Clin Invest 1986;77:528–37.
257. Psacharopoulos HT, Mowat AP, Cook PJL, et al. Outcome of liver disease associated with alpha-1-antitrypsin deficiency (Pi Z). Arch Dis Child 1983;58:882–7.
258. Thelin T, Sveger T, Mc Neil TF. Primary prevention in a highrisk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency. Acta Paediatr 1996;85:1207–12.
259. Wall M, Moe E, Eisenberg J, et al. Long-term follow-up of a cohort of childrenwith alpha-1-antitrypsin deficiency. J Pediatr 1990;116:248–51.
260. Mc Neil TF, Sveger T, Thelin T. Psychosocial effects of screening for somatic risk: the Swedish a1-antitrypsin experience. Thorax 1988;43:505–7.
261. Sveger T, Thelin T, Mc Neil TF. Young adultswitha1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997; 86:37–40.